JP2016501857A - 膵癌を処置するためのｃｄ４４ｖ６由来ペプチド - Google Patents

膵癌を処置するためのｃｄ４４ｖ６由来ペプチド Download PDF

Info

Publication number
JP2016501857A
JP2016501857A JP2015543431A JP2015543431A JP2016501857A JP 2016501857 A JP2016501857 A JP 2016501857A JP 2015543431 A JP2015543431 A JP 2015543431A JP 2015543431 A JP2015543431 A JP 2015543431A JP 2016501857 A JP2016501857 A JP 2016501857A
Authority
JP
Japan
Prior art keywords
group
peptide
amino acids
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015543431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501857A5 (enExample
Inventor
オリアン−ルソー，ベロニーク
マッケ，アレクサンドラ
ポンタ，ヘルムト
Original Assignee
アムキュア ゲーエムベーハー
アムキュア ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムキュア ゲーエムベーハー, アムキュア ゲーエムベーハー filed Critical アムキュア ゲーエムベーハー
Publication of JP2016501857A publication Critical patent/JP2016501857A/ja
Publication of JP2016501857A5 publication Critical patent/JP2016501857A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015543431A 2012-11-21 2013-11-21 膵癌を処置するためのｃｄ４４ｖ６由来ペプチド Pending JP2016501857A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1220901.1 2012-11-21
GBGB1220901.1A GB201220901D0 (en) 2012-11-21 2012-11-21 CD44v6-derived peptides for treating pancreatic cancer
PCT/EP2013/074401 WO2014079940A1 (en) 2012-11-21 2013-11-21 Cd44v6-derived peptides for treating pancreatic cancer

Publications (2)

Publication Number Publication Date
JP2016501857A true JP2016501857A (ja) 2016-01-21
JP2016501857A5 JP2016501857A5 (enExample) 2016-12-22

Family

ID=47521471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543431A Pending JP2016501857A (ja) 2012-11-21 2013-11-21 膵癌を処置するためのｃｄ４４ｖ６由来ペプチド

Country Status (5)

Country Link
US (1) US9586993B2 (enExample)
EP (1) EP2922561A1 (enExample)
JP (1) JP2016501857A (enExample)
GB (1) GB201220901D0 (enExample)
WO (1) WO2014079940A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
EP4464714A1 (en) 2023-05-19 2024-11-20 Karlsruher Institut für Technologie Screening method for cell-repelling peptides

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016557A1 (de) * 1995-10-31 1997-05-09 Boehringer Ingelheim International Gmbh TUMORTHERAPIE DURCH ADOPTIVEN TRANSFER CD44v-SPEZIFISCHER ZYTOTOXISCHER T-LYMPHOZYTEN
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
JP2004529963A (ja) * 2001-05-18 2004-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞傷害性ｃｄ４４抗体免疫コンジュゲート
WO2005065709A2 (de) * 2003-12-24 2005-07-21 Boehringer Ingelheim International Gmbh Gefriergetrocknete formulierung von antikörperkonjugaten
EP1647556A1 (en) * 2004-10-14 2006-04-19 TopoTarget Germany AG Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors
EP2218457A1 (en) * 2009-02-16 2010-08-18 Karlsruher Institut für Technologie CD44v6 peptides as inhibitors of bacterial infections
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases
WO2011022335A1 (en) * 2009-08-21 2011-02-24 Mount Sinai School Of Medicine Of New York University Methods of using cd44 fusion proteins to treat cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901710D0 (en) 1999-01-26 1999-03-17 Prolifix Ltd Peptide inhibitors
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
PT2193142E (pt) 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
US20120258998A1 (en) 2011-04-05 2012-10-11 Patrick Tan Fusion genes in gastrointestinal cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016557A1 (de) * 1995-10-31 1997-05-09 Boehringer Ingelheim International Gmbh TUMORTHERAPIE DURCH ADOPTIVEN TRANSFER CD44v-SPEZIFISCHER ZYTOTOXISCHER T-LYMPHOZYTEN
JP2004529963A (ja) * 2001-05-18 2004-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞傷害性ｃｄ４４抗体免疫コンジュゲート
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
WO2005065709A2 (de) * 2003-12-24 2005-07-21 Boehringer Ingelheim International Gmbh Gefriergetrocknete formulierung von antikörperkonjugaten
EP1647556A1 (en) * 2004-10-14 2006-04-19 TopoTarget Germany AG Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors
EP2218457A1 (en) * 2009-02-16 2010-08-18 Karlsruher Institut für Technologie CD44v6 peptides as inhibitors of bacterial infections
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases
WO2011022335A1 (en) * 2009-08-21 2011-02-24 Mount Sinai School Of Medicine Of New York University Methods of using cd44 fusion proteins to treat cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A MATZKE, ET AL., CANCER RES, 2005, 65(14), PP6105-6110, JPN6017034275, ISSN: 0003823484 *
M HOFMANN, ET AL., CANCER RESEARCH, 1991, 51, PP5292-5297, JPN6017034281, ISSN: 0003637326 *
M TREMMEL, ET AL., BLOOD, 2009, 114(25), PP5236-5244, JPN6017034277, ISSN: 0003823485 *
MARGOT ZOELLER, NATURE REVIEWS CANCER, vol. V11 N4, JPN5016002244, 10 March 2011 (2011-03-10), pages 254 - 267, ISSN: 0003637327 *
VERONIQUE ORIAN-ROUSSEAU, EUROPEAN J CANCER, 2010, 46, PP1271-1277, JPN6017034280, ISSN: 0003823486 *

Also Published As

Publication number Publication date
US9586993B2 (en) 2017-03-07
US20150166607A1 (en) 2015-06-18
EP2922561A1 (en) 2015-09-30
GB201220901D0 (en) 2013-01-02
WO2014079940A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
US11155603B2 (en) Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
US12121596B2 (en) Near infrared fluorescent dyes, formulations and related methods
US9593146B2 (en) CD44v6-derived peptides for treating metastasizing cancer
US9586993B2 (en) CD44v6-derived peptides for treating pancreatic cancer
WO2014079914A1 (en) Cd44v6-derived pegylated peptides
CA2931023C (en) Pharmaceutical compositions of isolated peptides for the treatment of metastatic cancer
US9586994B2 (en) CD44V6-derived peptides for treating breast cancer
US20170305995A1 (en) CD44V6-Derived Peptides for Treating Metastasizing Cancer
US20250001016A1 (en) Near Infrared Fluorescent Dyes, Formulations and Related Methods
HK1229242B (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer
HK1229242A1 (en) Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180626